Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
KLF17 Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application 
| WB, IHC-P, E |
|---|---|
| Primary Accession | Q5JT82 |
| Other Accession | NP_775755, 104294874 |
| Reactivity | Human, Mouse, Rat |
| Host | Rabbit |
| Clonality | Polyclonal |
| Isotype | IgG |
| Calculated MW | Predicted: 28, 39, 43 kDa Observed: 38 kDa |
| Application Notes | KLF17 antibody can be used for detection of KLF17 by Western blot at 1 - 2 µg/ml. Antibody can also be used for immunohistochemistry starting at 5 µg/mL. |
| Gene ID | 128209 |
|---|---|
| Target/Specificity | KLF17; KLF17 antibody is human, mouse and rat reactive. At least two isoforms of KLF17 are known to exist; this antibody will only detect the large isoform. KLF17 antibody is predicted to not cross-react with other KLF proteins. |
| Reconstitution & Storage | KLF17 antibody can be stored at 4℃ for three months and -20℃, stable for up to one year. |
| Precautions | KLF17 Antibody is for research use only and not for use in diagnostic or therapeutic procedures. |
| Name | KLF17 |
|---|---|
| Synonyms | ZNF393 |
| Function | Transcription repressor that binds to the promoter of target genes and prevents their expression. Acts as a negative regulator of epithelial-mesenchymal transition and metastasis in breast cancer. Specifically binds the 5'-CACCC-3' sequence in the promoter of ID1, a key metastasis regulator in breast cancer, and repress its expression. May be a germ cell-specific transcription factor that plays important roles in spermatid differentiation and oocyte development (By similarity). |
| Cellular Location | Nucleus. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
KLF17, also known as ZNF393, is a member of the Sp/KLF family of transcription factors (1,2). KLF17 binds to the promoter and negatively regulates the transcription of Id-1, a key metastasis regulator in breast cancer (3). Suppression of KLF17 promotes breast cancer cell invasion and epithelial-mesenchymal transition (3). Down-regulated KLF17 expression is also associated tumor invasion and poor prognosis in hepatocellular carcinoma, suggesting that the level of KLF17 expression can serve as a prognostic indicator (4).
References
Yan W, Burns KH, Ma L, et al. Identification of Zfp393, a germ cell-specific gene encoding a novel zinc finger protein. Mech. Dev. 2002; 118:233-9.
van Vliet J, Crofts LA, Quinlan KG, et al. Human KLF17 is a new member of the Sp/KLF family of transcription factors. Genomics 2006; 87:474-82.
Gumireddy K, Li A, Gimotty PA, et al. KLF17 is a negative regulator of epithelial-mesenchymal transition and metastasis in breast cancer. Nat. Cell Biol. 2009; 11:1297-304.
Liu FY, Deng YL, Li Y, et al. Down-regulated KLF17 expression is associated with tumor invasion and poor prognosis in hepatocellular carcinoma. Med. Oncol. 2013; 30:425.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
